Insider
SanofiSNY

Sanofi transferred 20 drugs to Cheplapharm, received a 26.4% stake and paid Regeneron $1 billion

Sanofi handed Cheplapharm 20 mature medicines, including Lovenox/Clexane, and three manufacturing sites, in exchange for a 26.4% stake in Cheplapharm; at the same time the company made a one‑time $1 billion payment to Regeneron to expand their global alliance with new immunology antibodies.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
Small pink pills tumbling on a machine surface
Photo by Sulyok Img on Unsplash
26.4%
Equity stake
$1 billion
Upfront payment
20
Mature medicines

Key points

  • Sanofi and Cheplapharm announced a strategic partnership under which Cheplapharm will take over 20 mature medicines, including Lovenox/Clexane, and three manufacturing sites in Hungary, Singapore and France, while preserving existing labor agreements and ensuring uninterrupted supply.
  • Sanofi will receive a 26.4% stake in Cheplapharm.

What happened

Sanofi and Cheplapharm announced a strategic partnership under which Cheplapharm will take over 20 mature medicines, including Lovenox/Clexane, and three manufacturing sites in Hungary, Singapore and France, while preserving existing labor agreements and ensuring uninterrupted supply.

Through the deal, Sanofi will receive a 26.4% stake in Cheplapharm.

At the same time Sanofi expanded its alliance with Regeneron, paying a $1 billion upfront and agreeing to split 50% of development and commercialization costs for four new antibodies, with Regeneron handling research and Sanofi leading global commercialization.

Deal terms

Sanofi will receive a 26.4% stake in Cheplapharm.

The Regeneron deal includes a one‑time $1 billion payment and an equal split of future costs and profits (50% each).

Key considerations

Changes in revenue from mature products, the valuation of the Cheplapharm stake and the payment schedule with Regeneron could affect Sanofi’s financial results.

Original sources

  1. 6-K EX-99.1 filing, September 17, 2026September 17, 2026SHA-256 of our archived copy 1bbb11b42247…
  2. 6-K EX-99.1 filing, October 1, 2026October 1, 2026SHA-256 of our archived copy 884173f3ed53…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards